Tolerability Study of Investigational Agent, ARRY-142886, in Patients With Cancer - Full Text View

Tolerability Study of Investigational Agent, ARRY-142886, in Patients With Cancer

This study is ongoing, but not recruiting participants.

Sponsored by:	Array BioPharma
Information provided by:	Array BioPharma
ClinicalTrials.gov Identifier:	NCT00085787

Purpose

The purpose of this study is to assess the tolerability of ARRY-142886 in patients with advanced solid malignancies that have failed standard therapy or for whom no standard therapy exists and determine the maximum tolerated dose as defined by significant dose limiting toxicity.

Condition	Intervention	Phase
Cancer	Drug: ARRY-142886	Phase I

Genetics Home Reference related topics:

Benign Tumors Cancer

MedlinePlus related topics:

Cancer

ChemIDplus related topics:

ARRY 142886

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Pharmacokinetics/Dynamics Study

Official Title:	A Phase I, Open-Label, Multiple Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of ARRY-142886 Given on a Daily Oral Regime in Subjects With Advanced Solid Malignancies

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Confirmed solid tumor which is refractory to standard therapies
At least 18 years old
Ambulatory with ECOG status of 0-2
Life expectancy of greater than or equal to 3 months

Exclusion Criteria:

Brain metastases
Use of investigational medication or device within 30 days
Major surgery within 30 days
Radiotherapy or chemotherapy within 21 days
Pregnant or lactating
Known positive for HIV

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00085787

Locations


United States, Colorado
	University of Colorado Cancer Center, Anschutz Cancer Center
	Aurora, Colorado, United States, 80010

United States, Minnesota
	Mayo Clinic Rochester
	Rochester, Minnesota, United States, 55905

United States, Pennsylvania
	Fox Chase Cancer Center
	Philadelphia, Pennsylvania, United States, 19111

Sponsors and Collaborators

Array BioPharma

More Information

Study ID Numbers:	ARRY-0401
First Received:	June 14, 2004
Last Updated:	July 12, 2007
ClinicalTrials.gov Identifier:	NCT00085787
Health Authority:	United States: Food and Drug Administration

ClinicalTrials.gov processed this record on July 03, 2008